Neurotez Inc.

[On Demand]
Search General Info
Search Education
Search Partnering Companies
Neurotez wants to overcome Alzheimer’s disease once and for all.

Our novel approach focuses on Leptin, a naturally occurring human hormone associated with various metabolic effects, has a large number of receptors in memory centers of the brain (hippocampus). The hippocampus is responsible for memory formation, cognition and executive function is severely affected by the disease. This region is rich in Leptin receptors.

This protein is often present at decreased levels in patients suffering from Alzheimer’s disease, and cognitive deterioration in AD patients correlates strongly with a decline in circulating Leptin levels.

We are developing Memtin™ to treat Leptin deficiency in Alzheimer’s patients.

This Leptin product will act as a novel hormone replacement therapy for Alzheimer’s disease (AD) and/or as a preventative for those who are at risk.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
2005
Main Therapeutic Focus:
Lead Product in Development:
Memtin
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
President & CEO
Neurotez, Inc.